FY2026 Earnings Estimate for BEAM Issued By HC Wainwright

Beam Therapeutics Inc. (NASDAQ:BEAM) – Research analysts at HC Wainwright issued their FY2026 earnings per share estimates for Beam Therapeutics in a report issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio expects that the company will earn ($3.30) per share for the year. HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ FY2027 earnings at ($3.00) EPS and FY2028 earnings at ($1.91) EPS.

A number of other research analysts also recently issued reports on the company. Sanford C. Bernstein raised Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Leerink Partners raised Beam Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $27.00 to $39.00 in a report on Wednesday, November 6th. Cantor Fitzgerald raised Beam Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Wednesday, January 29th. Leerink Partnrs raised Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. Finally, Scotiabank initiated coverage on Beam Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $24.00 price target for the company. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $47.67.

Beam Therapeutics Price Performance

Shares of BEAM opened at $27.82 on Wednesday. Beam Therapeutics has a 1-year low of $20.84 and a 1-year high of $49.50. The stock has a market cap of $2.30 billion, a PE ratio of -15.81 and a beta of 1.92. The firm has a fifty day moving average price of $26.49 and a 200 day moving average price of $25.77.

Beam Therapeutics (NASDAQ:BEAM) last issued its earnings results on Tuesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.01). Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The company had revenue of $14.30 million during the quarter, compared to analyst estimates of $14.52 million. During the same quarter in the previous year, the company posted ($1.22) EPS. The company’s quarterly revenue was down 16.9% on a year-over-year basis.

Insider Buying and Selling

In related news, CEO John M. Evans sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the sale, the chief executive officer now owns 908,659 shares in the company, valued at $24,306,628.25. This represents a 3.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total value of $30,627.88. Following the transaction, the insider now directly owns 102,968 shares of the company’s stock, valued at $2,541,250.24. This trade represents a 1.19 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Beam Therapeutics

Large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. lifted its stake in Beam Therapeutics by 6.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 629,492 shares of the company’s stock valued at $15,423,000 after buying an additional 36,226 shares in the last quarter. Bellevue Group AG raised its holdings in shares of Beam Therapeutics by 7.1% in the third quarter. Bellevue Group AG now owns 1,518,121 shares of the company’s stock worth $37,194,000 after acquiring an additional 100,000 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Beam Therapeutics by 4.5% in the third quarter. Geode Capital Management LLC now owns 1,807,683 shares of the company’s stock valued at $44,297,000 after acquiring an additional 78,102 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Beam Therapeutics by 59.7% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,552,829 shares of the company’s stock valued at $87,044,000 after acquiring an additional 1,328,414 shares during the last quarter. Finally, Algert Global LLC increased its position in Beam Therapeutics by 282.0% during the 3rd quarter. Algert Global LLC now owns 43,523 shares of the company’s stock worth $1,066,000 after purchasing an additional 32,130 shares in the last quarter. 99.68% of the stock is currently owned by institutional investors and hedge funds.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.